AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21915653 — intervention group
Group type: COMPARATOR
Intervention: Alert participants
Number of subjects: 202
Study 19755574 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 180
Study 19755574 — intervention group
Group type: COMPARATOR
Intervention: General Psychiatric Management (GPM)
Number of subjects: 180
Study 17688398 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Plus Program
Number of subjects: 209
Study 17688398 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Only
Number of subjects: 209
Study 17688398 — intervention group
Group type: EXPERIMENTAL
Intervention: Plus Only (motivation)
Number of subjects: 209
Study 17688398 — intervention group
Group type: COMPARATOR
Intervention: Routine Care
Number of subjects: 209
Study 15051743 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (500 mg bid)
Number of subjects: 0
Study 15051743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11806481 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose Plus with phosphoric acid and Z100
Number of subjects: 30
Study 11806481 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 1 after etching with phosphoric acid plus Z100
Number of subjects: 30
Study 11806481 — intervention group
Group type: EXPERIMENTAL
Intervention: F2000 with its Primer/Adhesive
Number of subjects: 30
Study 11806481 — intervention group
Group type: COMPARATOR
Intervention: Intact incisors (Group D)
Number of subjects: 30
Study 10193283 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Number of subjects: 60
Study 10193283 — intervention group
Group type: COMPARATOR
Intervention: Supine horizontal position
Number of subjects: 60
Study 10193283 — intervention group
Group type: EXPERIMENTAL
Intervention: Hammock position
Number of subjects: 60
Study 10193283 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg position (after 90 min)
Number of subjects: 60
Study 10193283 — intervention group
Group type: COMPARATOR
Intervention: Supine horizontal position (after 90 min)
Number of subjects: 60
Study 8113843 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (120 mg/m2 IV on day 1)
Number of subjects: 109
Study 8113843 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose cisplatin (30 mg/m2 IV on days 2 and 3) and carboplatin (200 mg/m2 IV on day 1)
Number of subjects: 109
Study 8113843 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose cisplatin and carboplatin
Number of subjects: 109
Study 8113843 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin
Number of subjects: 109
Study 3288695 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 micrograms cyclopenthiazide
Number of subjects: 68
Study 3288695 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms cyclopenthiazide
Number of subjects: 68
Study 3288695 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms cyclopenthiazide
Number of subjects: 68
Study 3288695 — intervention group
Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 68
Study 31931887 — intervention group
Group type: EXPERIMENTAL
Intervention: Transactional Analysis (TA) group-training, 8 sessions of 90 minutes each.
Number of subjects: 76
Study 31931887 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 76
Study 31155577 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide (MgO) co-administration
Number of subjects: 0
Study 26018671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.25 mg/kg bolus followed by 0.25 mg/kg/h infusion)
Number of subjects: 66
Study 26018671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg bolus followed by 0.3 μg/kg/h infusion)
Number of subjects: 66
Study 26018671 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 66
Study 25244801 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation training (sitting, walking, running in hot lab)
Number of subjects: 60
Study 25244801 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-dizzy training (revolving chair training for 10 times)
Number of subjects: 60
Study 23730989 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 65 years and older
Number of subjects: 32
Study 23730989 — intervention group
Group type: COMPARATOR
Intervention: Patients younger than 65 years
Number of subjects: 32
Study 23730989 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with longer duration of hypertension
Number of subjects: 32
Study 23730989 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lower basal metabolic index
Number of subjects: 32
Study 23730989 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes or chronic kidney disease
Number of subjects: 32
Study 20648203 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic only (Group I)
Number of subjects: 70
Study 20648203 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic mixed with non-particulate betamethasone (Group II)
Number of subjects: 70
Study 18037603 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing (Project CHAT)
Number of subjects: 42
Study 18037603 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study 16309554 — intervention group
Group type: COMPARATOR
Intervention: Transpupillary therapy (TTT) alone (Group A)
Number of subjects: 26
Study 16309554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (iTA) 4 mg followed by TTT (Group B)
Number of subjects: 26
Study 14615619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean maximum CIMT
Number of subjects: 0
Study 14615619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean common CIMT
Number of subjects: 0
Study 14615619 — intervention group
Group type: COMPARATOR
Intervention: Control groups from published RCTs
Number of subjects: 0
Study 11093285 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (3.3 microg/(kg min))
Number of subjects: 6
Study 11093285 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (1 mU/(kg min))
Number of subjects: 6
Study 11093285 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 6
Study 8875584 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg terbutaline sulfate
Number of subjects: 82
Study 8875584 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg terbutaline sulfate
Number of subjects: 82
Study 8875584 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg terbutaline sulfate
Number of subjects: 82
Study 8875584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 8444205 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Triggered Ventilation (PTV)
Number of subjects: 40
Study 8444205 — intervention group
Group type: COMPARATOR
Intervention: Conventional Ventilation
Number of subjects: 40
Study 3770037 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptichemio, Vincristine and prednisone (PTC‐VCR‐P)
Number of subjects: 75
Study 3770037 — intervention group
Group type: COMPARATOR
Intervention: melphalan and prednisone (MPH‐P)
Number of subjects: 75
Study 29732549 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800 mg QD
Number of subjects: 1351
Study 29732549 — intervention group
Group type: COMPARATOR
Intervention: Eslicarbazepine acetate (ESL) 400 mg QD
Number of subjects: 1351
Study 29732549 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 1351
Study 29732549 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not from Western Europe (WE)
Number of subjects: 1351
Study 29732549 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not taking carbamazepine (CBZ) at baseline
Number of subjects: 1351
Study 24297950 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg once weekly
Number of subjects: 512
Study 24297950 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 400 mg twice per day
Number of subjects: 512
Study 22459771 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (1,600 μg/d)
Number of subjects: 90
Study 22459771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 20201749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (LIS)
Number of subjects: 27
Study 20201749 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (LOS)
Number of subjects: 27
Study 17905275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 101
Study 17905275 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 101
Study 16033593 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nursing intervention for pain
Number of subjects: 62
Study 16033593 — intervention group
Group type: COMPARATOR
Intervention: Routine care only (Control)
Number of subjects: 62
Study 12161519 — intervention group
Group type: COMPARATOR
Intervention: Saline/Saline infusion
Number of subjects: 18
Study 12161519 — intervention group
Group type: COMPARATOR
Intervention: Saline/GHRH infusion
Number of subjects: 18
Study 12161519 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH infusion
Number of subjects: 18
Study 12161519 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 18
Study 10334442 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (1, 10, 100, and 1,000 microg/min for 5 min each)
Number of subjects: 18
Study 10334442 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazeprilat (25 microg/min) during adenosine infusion
Number of subjects: 18
Study 10334442 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (n = 4)
Number of subjects: 18
Study 10334442 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine (n = 4)
Number of subjects: 18
Study 7624461 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychotherapy with a religious perspective (15-20 sessions)
Number of subjects: 32
Study 7624461 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief psychotherapy without religious perspective)
Number of subjects: 32
Study 2568803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast medium (sodium meglumine diatrizoate)
Number of subjects: 20
Study 2568803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast medium (iopromide)
Number of subjects: 20
Study 2568803 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 61394 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 250 mug suspended in methyl ethyl cellulose ('Tylose') 6% solution
Number of subjects: 30
Study 61394 — intervention group
Group type: COMPARATOR
Intervention: Tylose alone
Number of subjects: 30
Study 30783061 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy old group
Number of subjects: 20
Study 30783061 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy young group
Number of subjects: 20
Study 30783061 — intervention group
Group type: COMPARATOR
Intervention: Psoriasis and atopic dermatitis groups
Number of subjects: 20
Study 27324934 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal infiltration of local anaesthesia (LA)
Number of subjects: 50
Study 27324934 — intervention group
Group type: COMPARATOR
Intervention: Palatal injections of 0.1 ml 2% lidocaine with 1:100,000 adrenaline
Number of subjects: 50
Study 25968966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulfate and magnesium citrate (PMC)
Number of subjects: 0
Study 25968966 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 0
Study 23292288 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-g testosterone gel daily for 6 months
Number of subjects: 209
Study 23292288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 20192950 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR genotype (L'L' vs S' allele) in males
Number of subjects: 862
Study 20192950 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR genotype (S'S' vs L' alleles) in females
Number of subjects: 862
Study 20192950 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR genotype (1 L' allele vs 2 L' alleles) in females
Number of subjects: 862
Study 19269837 — intervention group
Group type: EXPERIMENTAL
Intervention: Coseal sealant (CG)
Number of subjects: 203
Study 19269837 — intervention group
Group type: COMPARATOR
Intervention: Suture/stapling (SCG)
Number of subjects: 203
Study 16551902 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral blocks (PVB)
Number of subjects: 50
Study 12760869 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 1,200 mg q12h
Number of subjects: 36
Study 12760869 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 1,000 mg q8h
Number of subjects: 36
Study 12760869 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg q24h
Number of subjects: 36
Study 12760869 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 300 mg q12h
Number of subjects: 36
Study 12760869 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir 300 mg q12h
Number of subjects: 36
Study 10580184 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 809
Study 10580184 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 809
Study 10580184 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 809
Study 9085461 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoccult II test (HII)
Number of subjects: 6366
Study 9085461 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 6366
Study 9085461 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive HII test
Number of subjects: 6366
Study 9085461 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-examination
Number of subjects: 6366
Study 9085461 — intervention group
Group type: EXPERIMENTAL
Intervention: One year after work-up
Number of subjects: 6366
Study 8334889 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg norethisterone (NET) per day
Number of subjects: 45
Study 8334889 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg norethisterone (NET) per day
Number of subjects: 45
Study 8334889 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg norethisterone (NET) per day
Number of subjects: 45
Study 8334889 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study 3552837 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 1386
Study 3552837 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1386
Study 30216086 — intervention group
Group type: EXPERIMENTAL
Intervention: ALIS + GBT
Number of subjects: 336
Study 30216086 — intervention group
Group type: COMPARATOR
Intervention: GBT alone
Number of subjects: 336
Study 26876692 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) treatment, mean blood concentration at V1: 660 ng/ml, at V2: 1020 ng/ml, mean difference 366 units, p < 0.001
Number of subjects: 166
Study 26011959 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOL (ZAM00 group)
Number of subjects: 112
Study 26011959 — intervention group
Group type: COMPARATOR
Intervention: Accommodative IOL (FLEX group)
Number of subjects: 112
Study 22192095 — intervention group
Group type: EXPERIMENTAL
Intervention: +POWER
Number of subjects: 7
Study 20542472 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraSeal Xact Adhesion Barrier and Sealant System (DSX)
Number of subjects: 20
Study 20542472 — intervention group
Group type: COMPARATOR
Intervention: Control group (local standard of care)
Number of subjects: 20
Study 18562131 — intervention group
Group type: COMPARATOR
Intervention: TPH1 (Reference AA)
Number of subjects: 792
Study 18562131 — intervention group
Group type: EXPERIMENTAL
Intervention: TPH1 (AC)
Number of subjects: 792
Study 18562131 — intervention group
Group type: EXPERIMENTAL
Intervention: TPH1 (CC)
Number of subjects: 792
Study 18562131 — intervention group
Group type: COMPARATOR
Intervention: 5‐HTTLPR (Reference LL)
Number of subjects: 792
Study 18562131 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR (SL)
Number of subjects: 792
Study 18562131 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR (SS)
Number of subjects: 792
Study 18562131 — intervention group
Group type: COMPARATOR
Intervention: HTR1A (Reference CC)
Number of subjects: 792
Study 18562131 — intervention group
Group type: EXPERIMENTAL
Intervention: HTR1A (CG)
Number of subjects: 792
Study 18562131 — intervention group
Group type: EXPERIMENTAL
Intervention: HTR1A (GG)
Number of subjects: 792
Study 18562131 — intervention group
Group type: COMPARATOR
Intervention: 5‐HTTLPR (Reference LL) at 12-week follow-up
Number of subjects: 792
Study 18562131 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR (SL) at 12-week follow-up
Number of subjects: 792
Study 18562131 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR (SS) at 12-week follow-up
Number of subjects: 792
Study 18562131 — intervention group
Group type: COMPARATOR
Intervention: 5‐HTTLPR (Reference LL) at 26-week follow-up
Number of subjects: 792
Study 18562131 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR (SL) at 26-week follow-up
Number of subjects: 792
Study 18562131 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HTTLPR (SS) at 26-week follow-up
Number of subjects: 792
Study 16202353 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl 2 mg/kg
Number of subjects: 60
Study 16202353 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 2 mg/kg
Number of subjects: 60
Study 16202353 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 60
Study 12733727 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month whole body vibration (4 min/day, 3-5 times per week, oscillating from 25 to 45 Hz)
Number of subjects: 56
Study 12733727 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study 10546921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg once daily for 5 days)
Number of subjects: 11
Study 8913195 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 35
Study 8913195 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 35
Study 8913195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 1862217 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (600 LRU daily for 12 weeks)
Number of subjects: 155
Study 1862217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 7178704 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine aerosol
Number of subjects: 12
Study 7178704 — intervention group
Group type: COMPARATOR
Intervention: Normal saline aerosol
Number of subjects: 12
Study 30601950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir monotherapy 50 mg once daily
Number of subjects: 101
Study 30601950 — intervention group
Group type: COMPARATOR
Intervention: Continuation of cART
Number of subjects: 101
Study 29691526 — intervention group
Group type: EXPERIMENTAL
Intervention: Black pepper-based beverage (BPB) preload containing 20 mg gallic acid equivalent (GAE)
Number of subjects: 16
Study 29691526 — intervention group
Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 16
Study 26315860 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (administered for 3 months after an initial 3 months of observation)
Number of subjects: 18
Study 26315860 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention for 6 months)
Number of subjects: 18
Study 24699032 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtherapeutic dosages of cyclosporin A (CsA)
Number of subjects: 0
Study 24699032 — intervention group
Group type: COMPARATOR
Intervention: Conditioned stimulus (CS) without CsA
Number of subjects: 0
Study 22832147 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change communication intervention
Number of subjects: 959
Study 22832147 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 959
Study 19202050 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17496414 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU/LV followed by CPT-11
Number of subjects: 120
Study 17496414 — intervention group
Group type: COMPARATOR
Intervention: CPT-11 followed by 5-FU/LV
Number of subjects: 120
Study 15498188 — intervention group
Group type: EXPERIMENTAL
Intervention: Spasfon (80 mg intravenously)
Number of subjects: 97
Study 15498188 — intervention group
Group type: COMPARATOR
Intervention: Atropine (0.5 mg injected into the cervix)
Number of subjects: 97
Study 11848259 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-dose perindopril-indapamide combination
Number of subjects: 10000
Study 11848259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive modified-release gliclazide-based glucose control regimen
Number of subjects: 10000
Study 11848259 — intervention group
Group type: COMPARATOR
Intervention: Usual guidelines-based treatment
Number of subjects: 10000
Study 11848259 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 10000
Study 9865735 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (RA) therapy
Number of subjects: 36
Study 9865735 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 36
Study 9865735 — intervention group
Group type: EXPERIMENTAL
Intervention: RA therapy after relapse
Number of subjects: 36
Study 9865735 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy after relapse
Number of subjects: 36
Study 9865735 — intervention group
Group type: EXPERIMENTAL
Intervention: CRABP‐II mRNA levels in RA relapse cases
Number of subjects: 36
Study 9865735 — intervention group
Group type: EXPERIMENTAL
Intervention: RA protein binding activity in RA relapse cases
Number of subjects: 36
Study 7833225 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of an aqueous solution containing paracetamol, salicylate, diclofenac, and [125I]-albumin (0.1 to 0.2 ml)
Number of subjects: 5
Study 3122349 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (preoperative administration)
Number of subjects: 31